Tenecteplase REperfusion in Acute Ischemic sTroke Registry（TREAT）

Tenecteplase REperfusion in Acute Ischemic sTroke Registry

The aim of the study was to establish tenecteplase thrombolysis database and to investigate the effectiveness and safety of rhTNK-tPA in acute ischemic stroke patients.

Tenecteplase (TNK), as a newer fibrinolytic agent, has practical delivery advantages over alteplase that would make it a potential alternative. Several randomized controlled clinical trials demonstrated the noninferiority of TNK but the evidence on the effectiveness and safety of TNK in the real-world is insufficient.

This is a multi-center, prospective, registry cohort study that enrolled acute ischemic stroke patients treated with TNK thrombolysis in China.

Inclusion Criteria:

• Older than 18 years;
• Diagnosed as acute ischemic stroke；
• Time intervals ≤ 4.5 hours from stroke onset to thrombolysis with TNK(Perfusion imaging completed including CTA+CTP or MRA+PWI+DWI before thrombolysis if the time intervals from stroke onset to thrombolysis was ≥4.5 hours)；
• Thrombolysis with rhTNK-tPA and derivatives.

Exclusion Criteria:

• Unlikely to adhere to the study protocol or follow-up ( life expectancy ≤ 3 months)；
• Already participated in other interventional trials.